Description At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s lead product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through the FDA’s traditional 510(k) pathway while simultaneously reviewed through the FDA’s Software Precertification Pilot Program. For more information, visit us at www.peartherapeutics.com.
Specialties Pharmaceuticals, Mobile Healthcare, Substance Use Disorder, Neurogaming, Digital Healthcare, Biotechnology, Opiate Dependence
Address 200 State St, Boston, Massachusetts,
Address 02109, United States
Linkedin Source https://www.linkedin.com/company/pear-therapeutics